# Thermo Fisher Scientific Inc (TMO) fundamentals

Data as of 2026-11-04. NYSE, United States. Sector: Healthcare / Life Science Tools. Price $698.34, market value $258.7 billion.

## Valuation
- **P/E (trailing): 36.8×** (5-yr avg 32.5×, 3-yr avg 32.7×). Thermo Fisher Scientific Inc trades at 36.8× trailing earnings, close to its own five-year average of 32.5×. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 25.1×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 3.43**. A PEG of 3.43 means the P/E is high relative to expected earnings growth; the price already assumes a lot.
- **Price / sales: 5.5×**. Each dollar of revenue is priced at 5.5×.
- **Price / book: 4.7×**. The shares trade at 4.7× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: 2.9%** (5-yr avg 3.2%). Free cash flow equals 2.9% of the market value, in line with its five-year average of 3.2%.
- **Earnings yield: 2.7%**. The inverse of the P/E: 2.7% of the price is earned each year.

## Profitability
- **Operating margin: 17.9%**. 17.9% of revenue is left after running the business, a healthy level in most sectors.
- **Net margin: 15.0%**. 15.0% of each dollar of sales reaches the bottom line.
- **Return on equity: 12.6%**. 12.6% on shareholders' equity is solid.
- **Return on invested capital: 7.8%**. Return on all capital, debt included, is 7.8%.
- **Return on assets: 6.4%**. Each dollar of assets produces 6.4% of profit.

## Growth
- **Revenue growth (1 yr): 3.9%** (3-yr -0.3%/yr, 5-yr 6.7%/yr). Revenue grew 3.9% over the last year, against 6.7% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): 7.3%** (3-yr 0.2%/yr, 5-yr 2.1%/yr). Earnings per share rose 7.3%, roughly in step with revenue.
- **Free-cash-flow growth (3 yr): -3.1%/yr**. Free cash flow has compounded at -3.1% a year over three years, keeping pace with earnings: the growth is real cash.

## Financial health
- **Debt to equity: 0.80**. Debt is 0.80 times equity, moderate leverage.
- **Current ratio: 1.89** (quick 1.89). Current assets cover the next year's liabilities 1.89 times.
- **Piotroski F-score: 5/9**. 5 of 9 checks pass: mixed.

## Dividends
- **Dividend yield: 0.27%** ($1.84 per share, trailing). Thermo Fisher Scientific Inc yields 0.27%, a modest yield more typical of a growth-oriented payer.
- **Payout ratio: 9%** (9% of free cash flow). 9% of earnings goes out as dividends, leaving room to keep raising it.
- **Consecutive years of increases: 14**. 14 straight years of increases, a record that survived at least one recession.
- **Dividend growth (5 yr): 14.3%/yr** (1-yr 10.3%). The dividend has compounded at 14.3% a year over five years, doubling roughly every 5 years at that pace.

## Analyst view
- **Analyst consensus: strong_buy** (25 analysts). 25 analysts cover Thermo Fisher Scientific Inc; the consensus is strong_buy, with an average price target of $752.12 (+8% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 20.6%** (YTD 18.0%, 3-mo 18.9%). The shares are up 20.6% over twelve months including dividends.
- **From 52-week high: -1.9%** (60.4% above the low). Trading within 5% of its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 53**. An RSI of 53 is neutral.
- **Beta (1 yr): 0.61** (volatility 29%). Beta of 0.61 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=TMO · Page: https://foliofundamentals.com/stocks/tmo

Not investment advice.